The stock of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is a huge mover today! About 352,080 shares traded hands. Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has declined 25.59% since April 13, 2016 and is downtrending. It has underperformed by 29.52% the S&P500.
The move comes after 6 months positive chart setup for the $294.21 million company. It was reported on Nov, 15 by Barchart.com. We have $6.41 PT which if reached, will make NASDAQ:ARWR worth $117.68M more.
Analysts await Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to report earnings on December, 12. They expect $-0.37 EPS, up 11.90% or $0.05 from last year’s $-0.42 per share. After $-0.32 actual EPS reported by Arrowhead Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 15.63% negative EPS growth.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Ratings Coverage
Out of 3 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Arrowhead Research Corp has been the topic of 5 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) earned “Overweight” rating by Piper Jaffray on Friday, September 25. The stock of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has “Buy” rating given on Thursday, November 10 by Chardan Capital Markets. The rating was maintained by RBC Capital Markets with “Hold” on Wednesday, August 5. The rating was initiated by Cantor Fitzgerald on Friday, August 19 with “Buy”. On Thursday, May 19 the stock rating was initiated by Chardan Capital Markets with “Buy”.
According to Zacks Investment Research, “Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company’s proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.”
Insitutional Activity: The institutional sentiment decreased to 0 in 2016 Q2. Its down 0.54, from 0.54 in 2016Q1. The ratio turned negative, as 67 funds sold all Arrowhead Pharmaceuticals Inc shares owned while 0 reduced positions. 0 funds bought stakes while 0 increased positions. They now own 6,170 shares or 99.97% less from 18.16 million shares in 2016Q1.
Great West Life Assurance Company Can last reported 5,700 shares in the company. Hanson & Doremus Management, a Vermont-based fund reported 470 shares.
Insider Transactions: Since August 22, 2016, the stock had 0 insider purchases, and 1 sale for $160,000 net activity. $160,000 worth of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares were sold by Myszkowski Kenneth Allen.
More important recent Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) news were published by: Fool.com which released: “What’s Next for Arrowhead Pharmaceuticals, Inc. After the Stock Meltdown?” on November 10, 2016, also Fool.com published article titled: “Why Arrowhead Pharmaceuticals Inc. Is Plummeting Today”, Businesswire.com published: “Arrowhead Pharmaceuticals Provides Update on Heparc-2004 Study” on November 09, 2016. More interesting news about Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) was released by: Businesswire.com and their article: “Arrowhead Pharmaceuticals Presents New Data on ARC-AAT” with publication date: November 14, 2016.
ARWR Company Profile
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, incorporated on February 13, 2001, is a biopharmaceutical company. The Firm is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi therapeutics leverage this natural pathway of gene silencing to target and shut down specific disease causing genes. The Company’s products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. The Company’s ARC-520 is an RNAi therapeutic designed to treat chronic hepatitis B virus (HBV) infection by reducing the expression and release of new viral particles and viral proteins with the goal of achieving a functional cure for HBV. The Firm is conducting multiple Phase IIb clinical efficacy studies. The Company’s ARC-AAT is an unlocked nucleobase analog (UNA), which contains RNAi therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), a rare genetic disease that can damage the liver and lungs of affected individuals. The Firm is conducting a Phase Ib clinical trial for ARC-AAT. The study is a multi-center, randomized, placebo-controlled, double blind, single dose-escalation, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of ARC-AAT and the effect on circulating AAT levels.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.